Browse > Article

Association of Serum Level of 25 Hydroxy-Vitamin D with Prognostic Factors for Breast Cancer  

Kermani, Iraj Asvadi (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Kojidi, Habibeh Taghavi (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Gharamaleki, Jalil Vaez (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Sanaat, Zohreh (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Ziaei, Jamal Eivazi (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Esfahani, Ali (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Seifi, Sharareh (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Ghojazadeh, Morteza (Physiology Department, Tabriz Faculty of Medicine, Tabriz University of Medical Sciences)
Dolatkhah, Roya (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Kermani, Atabak Asvadi (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Rad, Elnaz Ghaemi (Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.12, no.6, 2011 , pp. 1381-1384 More about this Journal
Abstract
Background and aim: In recent years, there has been considerable interest in whether vitamin D inhibits breast cancer development. Experimental studies have shown that vitamin D promotes cell differentiation and retards or terminates proliferation of breast cancer cells. However, there is little evidence supporting the association of vitamin D and prognosis of breast cancer. Methods and Materials: In this analytic-descriptive study, 119 female patients with histological proven breast cancer were recruited in Tabriz oncology clinics in a 15-month period of time. History of chemotherapy, radiotherapy or receiving vitamin D/Ca supplements and presence of other malignancies were exclusion criteria. Serum level of 25 hydroxy vitamin D (25(OH)D) was measured in all patients. Results: One hundred and nineteen patients with a mean age of $50.4{\pm}12.6$ (26-76) years were enrolled in the study. Metastasis was present in 21.8% of the cases. Stage of tumor was I, II, III and IV in 11, 56, 26 and 26 patients, respectively. The Tumor grade was low in 37 cases, intermediate in 46 cases, and high in 36 cases. The P53, Ki-67, HER2, ER and PR were positive in 30.3%, 49.6%, 17.6%, 61.2% and 55.5% of the patients, respectively. The mean serum level of 25(OH)D was $15.7{\pm}17.8$ (4-122) ng/ml, deficient in 66 cases, insufficient in 36 cases and normal level in 17 cases. The median level of 25(OH)D was lower in the P53+ group in a borderline trend (17.3 vs. 13.6 ng/ml; p=0.07). The median level of 25(OH)D was significantly higher in the patients with metastasis, as well (27.7 vs. 12.0 ng/ml; p=0.03). There was no significant association between the serum level of 25(OH)D and other studied parameters. Conclusion: Based on our findings, there may be an association between the serum level of 25(OH)D and prognosis of breast cancer.
Keywords
Breast cancer; vitamin D; prognosis; Iran;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Abbas S , Linseisen J , Slanger T, et al (2008). Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large caese-control study. Carcinogenesis, 29, 93-9.
2 Abbas S, Chang-Claude J, Linseisen J (2009). Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer, 124, 250-5.   DOI   ScienceOn
3 Alagol F, Shihadeh Y, Boztepe H (2000). Sunlight exposure and vitamin D in Turkish women. J Endocrinol Invest, 23, 173-7.   DOI
4 Azizi F, Rais-Zadeh F, Mir Said Ghazi A (2000). Vitamin D deficiency in a group of Tehran Population. Research In Medicine, 4, 291-303.
5 Colton KW, James SY, Pirianov G (1999). Novel vitamin D analogues as anti-proliferative agents in cancer: cellular and molecular mechanisms of action. Curr Top Steroid Res, 2, 141-56.
6 Cui Y, Rohan TE (2006). Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev, 15, 1427-37.   DOI   ScienceOn
7 Dawodu A, Agarwal M, Hossain M (2003). Hypervitaminosis D and vitamin D deficiency in exclusively brest feeding infants and their mother in summer :a justification for vitamin D supplementation of brest-feeding infants. J Pediatr, 142, 169-73.   DOI   ScienceOn
8 DeVita VT , Lawrence TS, Rosenberg SA, et al(2008). DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 8th ed. Lippincott Williams & Wilkins, USA, 1606-54.
9 Eisman JA, Barkla DH (1987). Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res, 47, 21-5.
10 Frazier AL, Ryan CT, Rockett H (2003). Adolescent diet and risk of breast cancer. Breast Cancer Res, 5, R59-64.   DOI
11 Freedman OC, Goodwin PJ (2009). The Role of Vitamin D in Breast Cancer Recurrence. Am Soc Clin Oncolo, 1, 79-83.
12 Garland CF, Garland FC (1980). Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol, 9, 227-31.   DOI
13 Garland CF, Garland FC, Gorham ED (1990). Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med, 19, 614-22.   DOI   ScienceOn
14 Gissel T, Rejnmark L, Mosekilde L, Vestergaard P (2008). Intake of vitamin D and risk of breast cancer-A meta-analysis. J Steroid Biochemistry Molecular Biology, 111, 195-9.   DOI   ScienceOn
15 Goodwin PJ, Ennis M, Pritchard KI, et al (2009). Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol, 27, 3757-63.   DOI   ScienceOn
16 Goodwin PJ (2009). Vitamin D in Breast Cancer--the debate continues: An Expert Interview. Medscape, 12, 1-6.
17 Gorham ED, Garland FC, Garland CF (1990). Sunlight and breast cancer incidence in the USSR. Int J Epidemiol, 19, 820-4.   DOI
18 Haq M, Kremer R, Goltzman D, et al (1993). A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest, 91, 2416-22.   DOI   ScienceOn
19 Hashemipour S, Larijani B, Adibi H, et al (2004). Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health, 4, 38.   DOI
20 John EM, Schwartz GG, Dreon DM, et al (1999). Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev, 8, 399-406.
21 John EM, Schwartz GG, Dreon DM (1999). Vitamin D and breast cancer risk: the NHANES I Epidemiologic Follow-up Study, 1971-1975 to 1992. Cancer Epidemiol Biomarkers Prev, 8, 399-406.
22 Larsson SC, Bergkvist L, Wolk A (2009). Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women. Am J Clin Nutr, 89, 277-82.   DOI
23 Levi F, Pasche C, Lucchini F, et al (2001). Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer, 91, 260-3.   DOI   ScienceOn
24 Montazeri A, Vahdaninia M, Harirchi I, et al (2008). Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. Asia Pacific Family Medicine, 7, 1-7.   DOI   ScienceOn
25 Lin J, Manson JE, Lee IM, et al (2007). Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med, 167, 1050-9.   DOI   ScienceOn
26 Mantell DJ, Owens PE, Bundred NJ (2000). 1a,25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res, 87, 214-20.   DOI   ScienceOn
27 Mathiasen IS, Lademann U, Jaattela M (1999). Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res, 59, 4848-56.
28 Nakagawa K, Kawaura A, Kato S, et al(2005). 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis, 26, 429-40.
29 Palmieri C, MacGregor T, Girgis S, et al (2006). Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol, 59, 1334-6.   DOI   ScienceOn
30 Robien K, Cutler GJ, Lazovich D (2007). Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control, 18, 775-82.   DOI   ScienceOn
31 Rossi M, McLaughlin JK, Lagiou P, et al (2009). Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol, 20, 374-8.
32 Shin MH, Holmes MD, Hankinson SE, et al (2002). Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst, 94, 1301-11.   DOI
33 Simard A, Vobecky J, Vobecky JS (1991). Vitamin D deficiency and cancer of the breast: an unprovocative ecological hypothesis. Can J Public Health, 82, 300-3.
34 Van den Bemd GJCM, Pols HAP, van Leeuwen JPTM. (2000). Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. Curr Pharm Des, 6, 717-32.   DOI   ScienceOn
35 Van Weelden K, Flanagan L, Binderup L (1998). Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog EB1089. Endocrinology, 139, 2102-10.   DOI   ScienceOn
36 Witte JS, Ursin G, Siemiatycki J (1997). Diet and premenopausal bilateral breast cancer: a case-control study. Breast Cancer Res Treat, 42, 243-51.   DOI   ScienceOn